UNBELIEVABLE: Dgx - The Untold Story

Quest Diagnostics’ Quarterly Earnings Preview: What You Need to Know

Quest Diagnostics is set to report its Q3 earnings next month, with analysts expecting single-digit year-over-year EPS growth.

Barchart · Oct 5

Is Quest Diagnostics Stock Outperforming the Nasdaq?

Quest Diagnostics has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart · Sep 22

Quest Diagnostics Stock: Is Wall Street Bullish or Bearish?

While Quest Diagnostics has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart · Aug 25

Is Henry Schein Stock Underperforming the S&P 500?

Henry Schein has trailed behind the S&P 500 Index, yet Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart · Mar 24

How Is Quest Diagnostics’ Stock Performance Compared to Other Healthcare Stocks?

Quest Diagnostics has outpaced its healthcare peers over the past year, and analysts are maintaining a moderately positive outlook on its future performance.

Barchart · Mar 19

Do Wall Street Analysts Like Quest Diagnostics Stock?

Quest Diagnostics has outperformed the broader market over the past year, and analysts remain somewhat bullish about the stock’s prospects.

Barchart · Feb 18

The battle of the SuperPods: Nvidia challenges Huawei with Vera Rubin powered DGX cluster that can deliver 28.8 Exaflops with only 576 GPUs

Nvidia’s Rubin DGX SuperPOD delivers 28.8 Exaflops using 576 GPUs, combining compute, memory, and software to rival Huawei’s SuperPOD.

TechRadar · Jan 9

What You Need To Know Ahead of Quest Diagnostics' Earnings Release

Quest Diagnostics is expected to unveil its fourth-quarter results soon, and analysts expect a single-digit growth in earnings.

Barchart · Jan 5

How Is Henry Schein's Stock Performance Compared to Other Healthcare Stocks?

Despite Henry Schein’s underperformance relative to its peers, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart · Dec 18, 2025

Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?

Despite Bio-Techne’s weak performance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Barchart · Dec 16, 2025